Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | GMNN | O75496 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | APEX1 | P27695 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600897 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL14322640 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL20680343 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL19357333 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL16401654 | 0.93 | CYP2C19 (0.49) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL16401332 | 0.93 | CYP2C19 (0.49) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL16401330 | 0.93 | CYP2C19 (0.49) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL23534464 | 0.85 | CYP2C19 (0.43) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL366778 | 0.85 | CYP2C19 (0.43) | CYP1A2CYP2C19BLMHSD17B10GMNN | |
| SCHEMBL366777 | 0.85 | CYP2C19 (0.43) | CYP1A2CYP2C19BLMHSD17B10GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245225-A1 | STAPLED PEPTIDE PROTEOLYSIS TARGETING CHIMERAS (SP-PROTACS) AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-3986438-B1 | P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-12264185-B2 | Stabilized BCL9 peptides for treatment of aberrant Wnt signaling | WNTRX PHARMACEUTICALS INC. (US) | 2025-04-01 | — | — | US | claimed |
| EP-4519300-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-03-12 | — | — | EP | claimed |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2024-10-17 | — | — | US | claimed |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2024-09-26 | — | — | US | claimed |
| EP-4399220-A1 | ANTIVIRAL STRUCTURALLY-STAPLED SARS-COV-2 PEPTIDE- CHOLESTEROL CONJUGATES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3359180-B1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | claimed |
| US-11945846-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| US-20150291682-A1 | MIMETIC PEPTIDES | LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2015-10-15 | — | — | US | claimed |
| EP-2917234-A1 | MIMETIC PEPTIDES | Les Hôpitaux Universitaires de Genève (CH) | 2015-09-16 | — | — | EP | claimed |
| US-8933019-B2 | Antiviral cell-penetrating peptides | NEW YORK BLOOD CENTER, INC. (US) | 2015-01-13 | — | — | US | claimed |
| WO-2014072916-A1 | MIMETIC PEPTIDES | LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2014-05-15 | — | — | WO | claimed |
| US-20130059776-A1 | Antiviral Cell-Penetrating Peptides | NEW YORK BLOOD CENTER | 2013-03-07 | — | — | US | claimed |
| US-8324153-B2 | Antiviral cell-penetrating peptides | NEW YORK BLOOD CENTER, INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2283033-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | New York Blood Center (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | NEW YORK BLOOD CENTER | 2009-11-12 | — | — | US | claimed |
| WO-2009137532-A1 | ANTIVIRAL CELL PENETRATING PEPTIDES | NEW YORK BLOOD CENTER (US) | 2009-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124529-A1 | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | ACE2, SARS1, ACE | CYP1A2 4648/4885CYP2C19 4011/4885BLM 513/4885 |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | CYP1A2 4758/4885CYP2C19 4413/4885BLM 2084/4885 |
| US-20130059776-A1 | Antiviral Cell-Penetrating Peptides | ZC3HAV1, MAVS, HAVCR2 | CYP1A2 4845/4885CYP2C19 4477/4885BLM 3694/4885 |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | CYP1A2 4876/4885CYP2C19 4707/4885BLM 3040/4885 |
| US-11945846-B2 | Stapled intracellular-targeting antimicrobial peptides to treat infection | VIP, SPPL2B, HM13 | CYP1A2 4876/4885CYP2C19 4707/4885BLM 3040/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | CYP1A2 4873/4885CYP2C19 4797/4885BLM 2624/4885 |
| US-20090281041-A1 | ANTIVIRAL CELL-PENETRATING PEPTIDES | ZC3HAV1, MAVS, HAVCR2 | CYP1A2 4845/4885CYP2C19 4477/4885BLM 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.